Deal Watch: Gilead Hopes Glympse’s Synthetic Biomarkers Can Optimize NASH Trials
Executive Summary
Gilead partners with Glympse to optimize NASH trials, while Ironwood will work with Pear on digital therapies for GI disorders. An alliance between Leo and Ubiquigent yields an option agreement around two novel compounds.
You may also be interested in...
BIO 2021 Notebook: Best Practices For Business Development
The recently concluded BIO annual meeting included several sessions focused on the practice of business development. In this extra edition of our BIO 2021 notebook, Scrip collected observations about best practices for partnerships.
BIO 2021 Notebook: A Breakthrough Year For Emerging Companies?
News and views from day two of the BIO Digital annual meeting include the increasing number of small companies driving US product approvals, an update on the Reagan-Udall RWE Accelerator project and Merck & Co.'s Julie Gerberding on the need for continued HIV/AIDS research.
BIO 2021 Notebook: A Breakthrough Year For Emerging Companies?
News and views from day two of the BIO Digital annual meeting include the increasing number of small companies driving US product approvals, the US FDA's Patrizia Cavazzoni on science vs. emotion at advisory committees and Merck & Co.'s Julie Gerberding on the need for continued HIV/AIDS research.